Tang Capital Acquisition, a blank check company formed by Tang Capital and focused on development-stage biopharmaceutical companies, has filed with the U.S. Securities and Exchange Commission to raise $75 million in an initial public offering. The SPAC is introducing an unusual structure that eliminates founder shares, warrants and sponsor promote while pricing its shares at $25, well above the standard $10 SPAC IPO price.

$75 Million IPO With No Warrants or Rights

Tang Capital Acquisition plans to raise $75 million by offering 3.0 million shares at $25 each. Unlike most SPACs, the offering will not include units containing warrants or rights.

The $25 IPO price would also make Tang Capital Acquisition unusual within the SPAC market. According to the filing, it would be the first SPAC to price its IPO at something other than the standard $10 level since Executive Network Partnering Corp offered its novel CAPS units in September 2020.

Sponsor Plans Major Investment

Sponsor Tang Capital Management has indicated a non-binding interest in purchasing approximately $50 million of shares, representing about 67% of the proposed IPO.

The sponsor may purchase fewer shares if outside investor demand is strong, but it intends to acquire more than half of the offering. The anticipated sponsor investment is also central to the SPAC’s proposed structure, as the company believes it could reduce the risk of significant shareholder redemptions.

A No-Promote SPAC Structure

Tang Capital Acquisition describes itself as the first no-promote SPAC, or “np-SPAC.” The company will have a single class of shares, while the sponsor will not receive founder shares or warrants.

Instead, every share owned by Tang Capital Management will be purchased at the same $25 IPO price offered to public investors. The sponsor will also fund the company’s expenses, with those expenses expected to be repaid from interest earned on the IPO trust account.

The structure is intended to align the sponsor’s investment more closely with public shareholders by eliminating the traditional promote and separate founder securities.

Development-Stage Biopharma Focus

Tang Capital Acquisition plans to search for private, development-stage biopharmaceutical companies for a potential business combination.

The SPAC may pursue a company affiliated with Tang Capital or its officers or directors. Its stated corporate structure is positioned as an advantage in pursuing a transaction, particularly through the single share class, absence of a sponsor promote and anticipated sponsor investment.

Experienced Life Sciences Leadership

Tang Capital Acquisition is led by Kevin Tang, who serves as CEO and chairman. Tang is the founder and president of life sciences investment firm Tang Capital Management and CEO of Aurinia Pharmaceuticals.

He is joined by Michael Hearne, who serves as CFO of both Tang Capital and Aurinia Pharmaceuticals, and Ryan Cole, COO of Aurinia Pharmaceuticals, who serves as chief operating officer of the SPAC.

The leadership team’s existing involvement in life sciences investment and biopharmaceutical operations aligns with the SPAC’s stated focus on development-stage biotech companies.

Nasdaq Listing Details

Based in San Diego, California, Tang Capital Acquisition was founded in 2026 and plans to list on the Nasdaq under the symbol TCAA.

The company filed confidentially with regulators on August 31, 2026. LifeSci Capital and Raymond James are serving as joint bookrunners for the offering.

Market Context & Opportunities

Tang Capital Acquisition is entering the SPAC market with a structure designed to distinguish it from conventional blank check companies. The combination of a $25 share price, single share class, no sponsor promote and substantial anticipated sponsor investment gives the vehicle a different economic structure from traditional SPAC offerings.

Its focus on private, development-stage biopharmaceutical companies also places the SPAC within a sector where specialized investment expertise can be particularly relevant to evaluating clinical-stage opportunities.

Risks & Challenges

The proposed sponsor investment is described as non-binding, meaning the final level of participation could differ from the indicated $50 million commitment. The company must also identify and complete a business combination with a suitable target.

The possibility of pursuing a company affiliated with Tang Capital or its officers and directors creates an additional consideration for investors evaluating potential conflicts and transaction terms.

As with other SPACs, investors ultimately face uncertainty surrounding the identity, valuation and prospects of the eventual target company.

Closing Paragraph

Tang Capital Acquisition is seeking $75 million through an unconventional $25-per-share SPAC IPO aimed at development-stage biopharmaceutical companies. Its proposed no-promote structure, single class of shares and anticipated $50 million sponsor investment distinguish the vehicle from traditional SPACs and are designed to align sponsor participation more closely with public shareholders.